Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation
- PMID: 26606757
- DOI: 10.1111/tid.12486
Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation
Abstract
Background: Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at risk of numerous opportunistic infections. Pneumocystis jirovecii pneumonia (PJP) is a potentially life-threatening infection that can develop in immunocompromised individuals. Current prophylaxis for PJP includes trimethoprim-sulfamethoxazole (TMP-SMX), dapsone, atovaquone, or inhaled pentamidine (PEN), often with varying breakthrough rates. The use of intravenous (IV) PEN for PJP prophylaxis has been evaluated in pediatric patients.
Methods: A single-institution retrospective review of electronic medical records was conducted for patients who underwent allo-HSCT between January 2001 and May 2013 and who had received at least 1 dose of IV PEN for PJP prophylaxis. Data collected included patient demographics, diagnosis, previous chemotherapy, pre-transplant conditioning regimen, other medications, microbiology test results, and clinical outcomes.
Results: A total of 113 patients were included in the study. The median number of PEN doses administered per patient was 3 (range 1-23). IV PEN was primary PJP prophylaxis in 74 of the patients (65%) and second-line prophylaxis in 39 (35%) post transplant, with the majority switching from oral TMP-SMX. Side effects of IV PEN administration were minimal. No patients who received IV PEN prophylaxis developed PJP infection. No case of PJP was seen in patients who received other agents for PJP prophylaxis.
Conclusion: This retrospective study showed that IV PEN is very effective and well-tolerated prophylaxis for PJP; IV PEN can be considered a favorable alternative for PJP in situations where other agents might be contraindicated. Our findings provide strong support for prospective studies of IV PEN for PJP prophylaxis in adult HSCT recipients.
Keywords: PCP; Pneumocystis jirovecii pneumonia; allogeneic transplant; breakthrough; immunosuppression; pentamidine; toxicity.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.Cytotherapy. 2020 Jan;22(1):27-34. doi: 10.1016/j.jcyt.2019.11.002. Epub 2019 Dec 27. Cytotherapy. 2020. PMID: 31889628
-
Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00173-18. doi: 10.1128/AAC.00173-18. Print 2018 Aug. Antimicrob Agents Chemother. 2018. PMID: 29866879 Free PMC article.
-
Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients.Pediatr Transplant. 2015 May;19(3):326-31. doi: 10.1111/petr.12441. Epub 2015 Feb 25. Pediatr Transplant. 2015. PMID: 25712369
-
Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation.Pharmacol Res. 2018 Aug;134:61-67. doi: 10.1016/j.phrs.2018.06.010. Epub 2018 Jun 8. Pharmacol Res. 2018. PMID: 29890253 Review.
-
Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.Ann Pharmacother. 2016 Aug;50(8):673-9. doi: 10.1177/1060028016650107. Epub 2016 May 30. Ann Pharmacother. 2016. PMID: 27242349 Review.
Cited by
-
Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study.BMC Infect Dis. 2020 Jun 5;20(1):400. doi: 10.1186/s12879-020-05127-y. BMC Infect Dis. 2020. PMID: 32503449 Free PMC article.
-
Incidence of Pneumocystis Pneumonia in Immunocompromised Patients without Human Immunodeficiency Virus on Intravenous Pentamidine Prophylaxis: A Systematic Review and Meta-Analysis.J Fungi (Basel). 2023 Mar 25;9(4):406. doi: 10.3390/jof9040406. J Fungi (Basel). 2023. PMID: 37108861 Free PMC article. Review.
-
Pneumocystis jirovecii Pneumonia Prophylaxis with Intravenous Pentamidine in Adult Allogeneic Hematopoietic Stem Cell Transplant Patients.Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0083322. doi: 10.1128/aac.00833-22. Epub 2022 Oct 10. Antimicrob Agents Chemother. 2022. PMID: 36214573 Free PMC article.
-
Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list.Med Mycol. 2024 Jun 27;62(6):myae038. doi: 10.1093/mmy/myae038. Med Mycol. 2024. PMID: 38935910 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources